F-1: IceCure Medical Files for Resale of 16M Shares by Holders

IceCure Medical Ltd. has filed an F-1 registration statement for the resale of up to 16 million ordinary shares by selling shareholders, stemming from recent warrant issuances.

Summary

• The filing is a registration statement for the resale of up to 16,000,000 Ordinary Shares by identified selling shareholders.
• These shares are issuable upon the exercise of 8,000,000 Series B warrants and 8,000,000 Series C warrants.
• The company will not receive any proceeds from the sale of Ordinary Shares by the selling shareholders.
• However, the company will receive cash proceeds equal to the total exercise price of the Warrants that are exercised, which is $0.55 per share.
• A March 2026 Offering (registered direct offering and concurrent private placement) involved the sale of 8,000,000 Ordinary Shares at an offering price of $0.50 per share, generating approximately $4.0 million in gross proceeds for the company.
• The full exercise of the Warrants would result in an additional $8.8 million in gross proceeds to the company.
• Proceeds from the exercise of the Warrants are intended for working capital and other general corporate purposes.
• IceCure Medical Ltd. is a commercial-stage medical device company focused on cryoablation systems and technologies based on liquid nitrogen for treating tumors.
• Its lead product, the ProSense system, has received marketing authorization from the United States Food and Drug Administration (FDA) for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above.
• As of March 31, 2026, 81,180,045 Ordinary Shares were issued and outstanding.
• Assuming the exercise in full of all Warrants, 97,180,045 Ordinary Shares would be outstanding.
• The last reported closing price of the company's Ordinary Shares on the Nasdaq Capital Market on March 31, 2026, was $0.30 per share.
• The company is an emerging growth company and a foreign private issuer, electing to comply with certain reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed signal. While the company secured capital and has a clear product strategy, the substantial potential dilution and the current market price trading below recent offering and warrant exercise prices suggest investor caution and potential downward pressure on the stock.

Positives

• The company has the potential to receive $8.8 million in additional gross proceeds from the full exercise of Series B and Series C Warrants, which will be used for working capital and general corporate purposes.
• The ProSense system has received FDA marketing authorization for the local treatment of low-risk breast cancer in women aged 70 and above, demonstrating regulatory success and market access for its lead product.
• The company operates as a commercial-stage medical device company with proprietary cryoablation technology, offering a minimally invasive alternative to surgical intervention for various tumors.

Negatives

• The company will not receive any proceeds from the resale of Ordinary Shares by the selling shareholders, limiting direct capital infusion from this specific offering.
• There is significant potential for dilution for existing shareholders, as the exercise of all outstanding options, restricted share units, and warrants (including those from the March 2026 Offering and August 2025 Rights Offering) could increase the number of outstanding Ordinary Shares by approximately 31.7% (from 81,180,045 to 106,924,117).
• The market price of Ordinary Shares could decline due to the sales or proposed sales of a large number of shares by selling shareholders, or the perception of such sales.
• The last reported closing price on Nasdaq on March 31, 2026, was $0.30 per share, which is below the $0.50 offering price of the March 2026 Offering and the $0.55 warrant exercise price, indicating a potential disconnect between recent capital raise terms and current market valuation.
• The company does not anticipate paying any cash dividends on its Ordinary Shares in the foreseeable future, meaning capital appreciation is the sole source of potential return for shareholders.
• The market for Ordinary Shares has demonstrated varying levels of trading activity, with limited public float and historically low and sporadic trading volume, which may impair investors' ability to sell shares.

Risks

• Shareholders may experience significant dilution as a result of potential future financings, including the exercise of outstanding warrants and other equity securities.
• The issuance of additional Ordinary Shares or other ordinary share equivalents could decrease existing shareholders' proportionate ownership interest, diminish the relative voting strength of previously outstanding shares, and cause the market price of Ordinary Shares to decline.
• Sales of up to 16,000,000 Ordinary Shares by the selling shareholders, representing approximately 19.7% of outstanding shares prior to the offering, could cause the market price of Ordinary Shares to decline.
• The exercise of outstanding warrants from the August 2025 Rights Offering, including up to 5,000,000 shares for the largest existing shareholder, would increase outstanding Ordinary Shares by approximately 6.2% and could lead to further dilution and a decline in trading price.
• Future issuances or sales, or the potential for future issuances or sales, of Ordinary Shares may cause the trading price to decline and could materially impair the company's ability to raise capital through subsequent equity offerings.
• The company's amended and restated articles of association authorize the board of directors to issue additional Ordinary Shares or securities convertible or exchangeable into Ordinary Shares without shareholder approval, which could be substantially dilutive.
• An active trading market for Ordinary Shares may not be sustained, which could impair investors' ability to sell shares at a reasonable price, reduce the fair market value of shares, and hinder the company's ability to raise capital.
• The share price may be subject to substantial volatility, and shareholders may lose all or a substantial part of their investment due to various market and operational factors.
• Resales of Ordinary Shares in the public market by current shareholders during this offering could depress the market price.
• Investors may have difficulty enforcing judgments against the company, its directors, and management, particularly those residing outside the United States (Israel, People's Republic of China, and Hong Kong).
• Israeli courts may refuse to hear claims based on U.S. securities laws or may apply Israeli law, making the enforcement of U.S. securities law claims difficult and costly.
• There is uncertainty regarding whether courts in the People's Republic of China and Hong Kong would recognize or enforce judgments of United States courts predicated upon U.S. federal or state securities laws against directors located in those jurisdictions.

Future Outlook

The company intends to use the net proceeds from the exercise of the Warrants for working capital and other general corporate purposes. It plans to continue investing in research and development to develop technology for both existing and new products. The company also aims to enroll the required number of patients for its post-market surveillance study for ProSense in low-risk breast cancer, maintain relationships with suppliers and partners, and obtain and protect intellectual property and regulatory approvals. Efforts will also focus on retaining key executive members and educating medical professionals about product use cases.

Management Comments

• "We intend to use the net proceeds from the March 2026 Offering for working capital and other general corporate purposes."

Industry Context

StockSavvy.ai notes that the cryoablation market is a growing segment within minimally invasive oncology treatments, offering alternatives to traditional surgery. The company's focus on FDA-authorized products like ProSense positions it within a competitive landscape where regulatory approvals and clinical data are crucial for market penetration and adoption. The capital raise, while dilutive, provides necessary funding to continue R&D and commercialization efforts in this specialized medical device sector.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• **Shareholders:** Face potential significant dilution from the exercise of warrants and future equity offerings. The market price of their shares may experience volatility due to large-scale resales. They may also encounter difficulties enforcing judgments against non-U.S. directors and management.
• **New Investors (from selling shareholders):** Have the opportunity to acquire shares, but the current market price is below the recent offering and warrant exercise prices, suggesting a potentially unfavorable entry point relative to recent capital raises.
• **Company:** Benefits from potential capital infusion from warrant exercises, which will support working capital and general corporate purposes. It maintains flexibility as an emerging growth company and foreign private issuer with reduced reporting requirements.
• **Management:** Continues to focus on strategic objectives, including R&D, regulatory approvals, and market education, while navigating the implications of capital structure changes and market perception.

Next Steps

• Selling shareholders may sell all or a portion of the Ordinary Shares from time to time in market or negotiated transactions.
• The company intends to use proceeds from the exercise of Warrants for working capital and other general corporate purposes.
• The company plans to continue investing in research and development for existing and new products.
• The company will continue efforts to enroll patients for its post-market surveillance study for ProSense in low-risk breast cancer.
• The company will file annual reports on Form 20-F and submit unaudited interim financial information on Form 6-K with the SEC.

Key Dates

Recommendation

The company has recently completed a capital raise and has a clear product strategy with FDA authorization for its ProSense system. However, the significant potential for dilution from outstanding warrants and the current market price trading below recent offering and warrant exercise prices introduce considerable uncertainty. Investors should hold to monitor the company's ability to execute its strategy, improve market valuation, and manage the dilutive effects of future share issuances.

Keywords

Cryoablation, Medical Device, Oncology, Breast Cancer, ProSense, FDA Authorization, Warrants, Dilution, SEC Filing, F-1 Registration, Nasdaq, Foreign Private Issuer, Emerging Growth Company